Fresenius Medical Care AG – Consensus indicates upside potential of 12.2%

Fresenius Medical Care SA found using the ticker (FMS) now have 3 analysts covering the stock. Analyst consensus points to a ‘Hold’ rating. The target price ranges between 45.56 and 30.02 and has an average objective at 37.41. Now, with the previous closing price of 33.35, this would imply an upside potential of 12.2%. The 50-day moving average now sits at 32.85 and the 200-day moving average is at 34.84. The company has a market cap of $20,009 million. Company website: https://www.freseniusmedicalcare.com

The potential market capitalization would be $22,445 million based on market consensus.

You can now share it on Stocktwits, just click on the logo below and add the ticker in the text to be seen.

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure. The company also develops, manufactures and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granules, bloodlines, kidney pharmaceuticals and water treatment systems; and non-dialyzed products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires and licenses renal pharmaceuticals; provides kidney medications and supplies to patients at home or in dialysis clinics; and provides vascular, cardiovascular and endovascular specialty services, an outpatient vascular surgery center, and nephrology and cardiology medical services. The company sells its products directly to dialysis clinics, hospitals and specialty treatment clinics, as well as through local sales forces, independent distributors, resellers and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.


Source link